NASDAQ · XXII

22nd Century Group Inc.

$4.27 -$0.38 (-8.17%) 1D Market open

Key Metrics

$1.60M
Market cap
P/E · TTM
Revenue · TTM
−$3.99M
Net income
EPS · TTM $-772.38
Dividend yield
Free cash flow −$7.94M
Beta · 1Y 1.64
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 29
    From its Jan 29 high, the share price fell 97%.

    Peak close $153.80 on Jan 29; trough close $3.90 on Jun 29. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -97%
  • Jun 9
    The stock moved -29.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 9
  • May 4
    The stock moved -27.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.60M
Enterprise value
Shares outstanding345.1K
52-wk range$0.75 – $297.00
Avg volume · 20D123.5K
Net cash
Book value / share$4,110.42
IndustryCigarettes
ExchangeNASDAQ
About 22nd Century Group Inc.
IPO dateJan 26, 2011
Employees32

22nd Century Group Inc is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -18.8% · —

Financial Health

Current ratio2.67
Quick ratio2.12
Debt / equity
Debt / EBITDA
Net cash
Working capital$13.16M

Cash Flow · TTM

Operating CF −$7.85M
Capex −$91.00K
Free cash flow −$7.94M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings